Elevance Health Inc.ANTMNYSE
Loading
Elevance Health (formerly Anthem) is the second-largest U.S. health insurer by revenue, serving approximately 47 million medical members across commercial employer groups, individual ACA exchanges, Medicaid, and Medicare Advantage plans. The company operates Blue Cross Blue Shield-licensed plans in 14 states and generates additional revenue through Carelon, its integrated health services division providing pharmacy benefits management, behavioral health, and care management solutions to third parties.
Elevance collects insurance premiums from members and employers, then manages medical costs through network negotiations with providers, utilization management, and care coordination. The company earns underwriting profit when medical loss ratios (MLR) remain below premium revenue after administrative costs. Typical commercial MLRs run 82-85%, while government programs operate at 85-88% due to regulatory requirements. Carelon generates fee-based revenue by providing healthcare services to both Elevance members and external clients, creating diversification beyond underwriting risk. Pricing power derives from scale advantages in provider negotiations, proprietary data analytics for risk adjustment, and regulatory barriers to entry in government programs.
Medical Loss Ratio (MLR) performance versus guidance - every 10-20 basis point variance materially impacts earnings
Medicare Advantage membership growth and Star Ratings (4+ stars unlock quality bonuses worth $1,000+ per member annually)
Medicaid redetermination impacts following pandemic-era continuous enrollment unwinding (completed by mid-2024, affecting 15M+ members industry-wide)
Government reimbursement rate changes - CMS Medicare Advantage rate updates (typically announced in April) and state Medicaid rate adequacy
Carelon revenue growth and margin expansion as the services business scales with external clients
Regulatory risk from potential Medicare Advantage payment reforms, including risk adjustment methodology changes that could reduce revenue by 3-5% if implemented
Political risk of expanded government healthcare programs (Medicare expansion, public option) that could displace commercial membership
Structural healthcare cost inflation (hospital labor shortages, specialty drug costs) outpacing premium rate increases, compressing margins
Technology disruption from direct-to-consumer telehealth and retail clinic expansion (CVS, Amazon, Walmart) disintermediating traditional insurance models
Intense competition for Medicare Advantage members from UnitedHealth, Humana, and CVS/Aetna, with aggressive $0 premium plans eroding margins
Loss of Blue Cross Blue Shield licenses in key states (though unlikely, would eliminate brand advantage and provider network access)
Vertical integration by competitors (UnitedHealth's Optum, CVS/Aetna) creating cost advantages through owned provider networks and PBM operations
Amazon and other tech entrants leveraging data analytics and consumer experience to capture younger, healthier commercial members
Reserve adequacy risk if medical cost trends accelerate unexpectedly (COVID-related deferred care, GLP-1 drug utilization, behavioral health demand)
Regulatory capital requirements limiting financial flexibility - state RBC ratios must exceed 200-300% of company action level
Pension and OPEB obligations, though relatively modest compared to industrial companies
Share repurchase commitments ($4B+ annually) could strain liquidity if operating cash flow deteriorates from MLR spikes
moderate - Commercial membership correlates with employment levels, as 60% of Americans under 65 receive employer-sponsored coverage. Economic downturns reduce commercial enrollment but increase Medicaid eligibility, partially offsetting revenue declines. Healthcare utilization shows counter-cyclical elements (deferred care during recessions, catch-up demand during recoveries). Government programs (60% of premium revenue) provide stability through multi-year contracts, though state budget pressures during recessions can compress Medicaid rates.
Rising rates modestly benefit investment income on $30B+ investment portfolio (primarily fixed-income securities backing claim reserves), adding 5-10 cents per share in EPS for every 100bp rate increase. However, higher rates increase discount rate for equity valuation, compressing P/E multiples. Minimal debt refinancing risk given low leverage (0.73x D/E) and staggered maturity profile. Rate impacts on economic activity indirectly affect commercial membership through employment trends.
Minimal direct credit exposure. The company maintains investment-grade bond portfolio with limited high-yield allocation. Provider payment risk is managed through contractual terms and state guaranty funds for Medicaid. Premium receivables from employer groups carry low default risk. Primary credit sensitivity is indirect through economic impacts on commercial membership and state fiscal health affecting Medicaid funding adequacy.
value - Trades at 0.4x P/S and 1.7x P/B, below historical averages and peers, attracting value investors seeking healthcare exposure with defensive characteristics. Generates $3.2B annual free cash flow supporting 2.8% FCF yield and consistent share buybacks. Dividend yield around 1.5% appeals to income-focused investors. Moderate 13% ROE and stable government revenue base (60% of premiums) attract risk-averse institutional investors seeking healthcare sector exposure without biotech volatility.
moderate - Beta typically 0.8-1.0, exhibiting lower volatility than broader market due to recurring revenue model and government contract stability. However, quarterly earnings can drive 5-10% single-day moves on MLR surprises or membership guidance changes. Regulatory announcements (CMS rate updates, policy changes) create event-driven volatility. Stock underperformed in 2025 (8.7% vs S&P 500) reflecting sector headwinds from Medicaid redetermination and Medicare Advantage margin pressure.